Despite high incidence rates and substantial financial burdens associated with the care of patients with bladder cancer, progress in bladder cancer management has been modest and no new therapeutic agents for bladder cancer have been approved over the past decades. Fortunately, a substantial improvement in our understanding of the biology of this disease has occurred owing to revolutionizing molecular analysis platforms and increased interest among physicians and scientists in bladder cancer. As a consequence, a number of promising novel therapeutic agents are in development and are expected to make their way into clinics in the near future. This review focuses on the unique aspects of current bladder cancer research that support the assertion that bladder cancer is a likely frontier for major advancements soon.